https://medlineplus.gov/multiplemyeloma.html The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical...
site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit theInternational Myeloma FoundationorHealthTree for Multiple Myeloma....
Multiple myeloma (MM) is an osteolytic malignancy that is incurable due to the emergence of treatment resistant disease. Defining how, when and where myeloma cell intrinsic and extrinsic bone microenvironmental mechanisms cause relapse is challenging wit
Multiple myelomaQuality of lifeMultiple myeloma is a bone marrow neoplasia with an incidence of 6/100,000/year in Europe. While the disease remains incurable, the development of novel treatments such as autologous stem cell transplantation, proteasome inhibitors and monoclonal antibodies has led to ...
The second-generation proteasome inhibitor carfilzomib is showing noteworthy response rates and low levels of adverse side effects among multiple myeloma patients in a phase II clinical trial, researchers reported today at the 51st Annual Meet
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been made to improve clinical outcomes and to prolong patients’ survival in the past two decades, MM remains la
Patients with multiple myeloma (MM) seem to be at increased risk for more severe COVID-19 infection and associated complications due to their immunocompromised state, the older age and comorbidities. The European Myeloma Network has provided an expert co
The Pharmacy Times® Multiple Myeloma Resource Center is a comprehensive resource for clinical news and expert insights on issues related to cancer that forms in a type of white blood cell.
EP: 1.Multiple Myeloma: Challenges in Diagnosis and Role of Multidisciplinary Care EP: 2.Educating on Multiple Myeloma: Patient and Physician Resources EP: 3.Role of Diagnostic Testing in Patients with Multiple Myeloma EP: 4.Treatment Considerations for Patients with Newly Diagnosed Multiple Myel...
Over the past 13 years, there have been advances in characterizing the patient experience in oncology trials, primarily using patient-reported outcomes (PROs). This review aims to provide details on the PRO measures and analyses used in multiple myeloma (MM) registrational trials. We identified re...